Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer | ||
By: GlobeNewswire - 23 May 2022 | Back to overview list |
|
The partnership will evaluate Lupagen’s extracorporeal in vivo delivery technology as a potential additional route of administration for Umoja’s VivoVec therapeutics SEATTLE and DALLAS, May 23, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, and Lupagen, Inc., a gene therapy company developing first-in-class gene delivery technologies for CAR-T, gene editing and immunotherapy products, today announced they have entered into a collaboration to evaluate extracorporeal in vivo delivery as a potential additional route of administration for Umoja’s VivoVec particles using Lupagen’s Side CAR-T™ technology. Lupagen’s patient connected extracorporeal Side CAR-T™ delivery system is expected to enable efficient and highly controlled viral vector targeting of T cells in a convenient bedside procedure without requirements for lymphodepleting chemotherapy. “Today’s cellular therapies are often hampered by lengthy delays to patient treatment with a weeks-to-months wait for cell manufacturing and release. Pairing Lupagen’s technology with Umoja’s in vivo therapeutics offers a compelling solution to one of the greatest challenges to receiving cellular therapies today,” said David Fontana, Ph.D., Chief Business and Strategy Officer at Umoja. “Putting patients first is not just about building better therapies, it’s about reimagining the patient experience by giving more control to the patients and providers to enable timely and controlled delivery.” David Peritt, Ph.D., Chief Scientific Officer, and co-founder of Lupagen, added, “Lupagen’s core focus is to make gene therapies broadly accessible using our extracorporeal in vivo gene delivery system. This partnership seeks to transform patient care by pairing Lupagen’s novel extracorporeal gene delivery technology with Umoja’s next-generation in vivo therapeutics to revolutionize cancer treatment. The familiarity of healthcare providers with extracorporeal bedside procedures will enable greater uptake and access to life-changing therapies across a wider range of patients. We look forward to working with Umoja to enhance the potential of their VivoVec particles with the highly controlled targeted delivery Lupagen’s technology can offer.” Under the terms of the agreement, both parties will collaborate to evaluate VivoVec delivery using the Side CAR-T™ system. Lupagen will not develop or commercialize the Side CAR-T™ device for the delivery of viral vectors in the field of oncology during the term of the agreement. Umoja retains the right to opt in to an exclusive, worldwide agreement to develop the Side CAR-T™ device in the field of oncology. About Umoja Biopharma About Lupagen Cautionary Note Regarding Forward-Looking Statements Media Contact:
|
||
|
||
Copyright 2022 GlobeNewswire | Back to overview list |